Search results for "Clinical Study"

showing 10 items of 211 documents

A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence doe…

2015

It is still uncertain if targeted therapy-based regimens in advanced gastric cancer actually produce survival benefit. To shed light on this important question, we performed a systematic review and meta-analyses on each relevant targeted-pathway. By searching literature databases and proceedings of major cancer meetings in the time-frame 2005–2014, 22 randomized clinical trials exploring targeted therapy for a total of 7022 advanced gastric cancer patients were selected and included in the final analysis. Benefit was demonstrated for antiangiogenic agents in terms of overall survival (HR 0.759; 95%CI 0.655–0.880; p < 0.001). Conversely no benefit was found for EGFR pathway (HR 1.077; 95%…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentAngiogenesis InhibitorsBioinformaticsTargeted therapylaw.inventionTargeted therapyRandomized controlled trialTargeted pathwayStomach NeoplasmlawStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMeta-analysiMolecular Targeted TherapySystemic chemotherapySurvival analysisRandomized Controlled Trials as TopicPharmacologyAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerAdvanced gastric cancermedicine.diseaseSurvival AnalysisErbB ReceptorsAngiogenesiPooled analysisOncologyTolerabilityMeta-analysisClinical StudyMolecular MedicineReceptor Epidermal Growth FactorSurvival AnalysiRandomized clinical trialbusinessGastric cancerAngiogenesis InhibitorHuman
researchProduct

Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a stu…

2012

Background: Hypothesising that cancer of unknown primary (CUP) may harbour unique characteristics, we present a translational study of the immunohistochemical expression and clinical correlation of key PTEN/AKT pathway molecules. Patients and methods: We collected 100 paraffin-embedded CUP tissue blocks. We studied using tissue microarrays the expression of PTEN, phospho-AKT, Cyclin D1, p21, phospho-RPS6. From the percentage of staining tumour cells and the literature, we selected cut-offs to classify the expression of each biomolecule. We correlated IHC expression with clinical data. Results: PTEN, pAKT, and pRPS6 showed frequent expression. At univariate analysis, high IHC expression of p…

OncologyMalePathologyP21Signal transductionMitogen activated protein kinaseTissue microarrayCancer riskNeoplasmsSquamous cell carcinomaCarcinomatous peritonitisCancer of unknown primary (cup)MedicineOverall survivalPriority journalSurvival timeUnivariate analysisTissue microarraybiologyUnknown primaryHematologyClassificationPrognosisImmunohistochemistryPtenRetrospective studyOncologyIntracellular signalingImmunohistochemistryFemaleCyclin d1Cancer tissueProtein p21HumanSignal Transductionmedicine.medical_specialtyTranslational studyMajor clinical studyCancer mortalityAdenocarcinomaArticleCyclin D1Disease associationInternal medicineTissue array analysisPTENHumansHuman tissueProtein kinase BPI3K/AKT/mTOR pathwayCancer prognosisSurvival predictionDigestive system cancerbusiness.industryAkt/PKB signaling pathwayAktCancer of unknown primary siteProto-oncogene proteins c-aktRps6Protein kinase bTissue Array Analysisbiology.proteinProtein expressionProgression free survivalProtein s6Neoplasms Unknown PrimarybusinessTissue preparationProto-Oncogene Proteins c-aktAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma

2013

Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis. Incidence and mortality rates are increasing in many geographical regions, indicating a need for better management strategies. Among several risk factors for HCC, the most common are cirrhosis because of chronic hepatitis B virus or hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In some patients, combined risk factors present additional challenges to the prevention and treatment of HCC. Screening and surveillance of high-risk populations varies widely by geographic regions, and access to optimal surveillance is critical for early diagnosis. The treatment choice for HCC depends on the canc…

OncologySorafenibmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationInternal medicineHepatectomyHumansMedicineChemoembolization TherapeuticPrecision MedicineEarly Detection of CancerNeoplasm StagingHepatologybusiness.industryClinical study designLiver NeoplasmsGastroenterologymedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationClinical trialTransplantationTreatment OutcomeHepatocellular carcinomaCatheter AblationLiver functionPersonalized medicinebusinessmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?

2014

Abstract: In the past decade, the advent of targeted therapy led to a silent revolution in the war against lung cancer and a significant evolution on the concept of Phase I clinical trials design. Thanks to the specificity of their target, the new drugs have radically changed NSCLC treatment, leading to the development of personalized strategies. The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development, characterized by modern, biomarker-driven, early clinical trial design and shorte…

Oncologymedicine.medical_specialtyPathologyLung NeoplasmsPyridinesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryEML4-ALKCeritinibNSCLCTargeted therapyPanacea (medicine)CrizotinibCarcinoma Non-Small-Cell LungInternal medicineDrug DiscoveryHumansMedicineAnaplastic Lymphoma KinaseMolecular Targeted TherapySulfonesPrecision MedicineLung cancerDrug ApprovalProtein Kinase InhibitorsGene RearrangementPharmacologyCeritinib; Crizotinib; EML4-ALK; NSCLCClinical Trials Phase I as TopicCrizotinibCeritinibbusiness.industryPharmacology. TherapyClinical study designReceptor Protein-Tyrosine Kinasesmedicine.diseaseCeritinib Crizotinib EML4-ALK NSCLCClinical trialPyrimidinesDrug DesignPyrazolesMolecular MedicineAccelerated approvalbusinessmedicine.drugExpert Opinion on Therapeutic Targets
researchProduct

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK …

2013

Background: Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer. Methods: Two dose levels (I/II) were defined: capecitabine 850/1000 mg m−2 twice daily on days 1–14; oxaliplatin 100/130 mg m−2 on day 1; bevacizumab 7.5 mg kg−1 on day 1; imatinib 300 mg day−1 on days 1–21 every 21 days. The primary study endpo…

OncologysafetyAdultMaleCancer Researchmedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentcolorectal cancerbevacizumabAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalDrug Administration SchedulePiperazinesCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesCapecitabineAgedAged 80 and overChemotherapybusiness.industrySunitiniboxaliplatinMiddle Agedmedicine.diseaseSurgeryOxaliplatinImatinib mesylatePyrimidinesTreatment OutcomeOncologyimatinibFluorouracilBenzamidesClinical StudyImatinib MesylateFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugBritish Journal of Cancer
researchProduct

Comparison of the retention strengths of three complete denture adhesives: An in vivo study

2009

One of the main problems posed by complete dentures is retention and stability. In order to solve this problem, dentists and the dental industry for a long time have attempted to improve denture adhesion by developing a range of "glues" of highly varied composition and efficacy. The present in vivo clinical study evaluates whether the adhesives used to improve complete denture retention are truly effective and able to increase denture adhesion to the mucosa covering the edentulous alveolar ridge.of the mandibular dentures. An in vivo clinical study is made of 30 patients with complete mandibular dentures to evaluate the retention afforded by three commercial complete denture adhesives (Benf…

OrthodonticsDenture Completebusiness.industrymedicine.medical_treatmentEdentulous alveolar ridgeDentistryOdontología:CIENCIAS MÉDICAS [UNESCO]Denture RetentionClinical studyOtorhinolaryngologyAdhesivesDenture adhesivesUNESCO::CIENCIAS MÉDICASMedicineHumansSurgeryDenturesbusinessGeneral DentistryDenture RetentionEdentulous patient
researchProduct

A smart rotary technique versus conventional pulpectomy for primary teeth: A randomized controlled clinical study.

2017

Background Techniques with adequate accuracy of working length determination along with shorter duration of treatment in pulpectomy procedure seems to be essential in pediatric dentistry. The aim of the present study was to evaluate the accuracy of root canal length measurement with Root ZX II apex locator and rotary system in pulpectomy of primary teeth. Material and methods In this randomized control clinical trial complete pulpectomy was performed on 80 mandibular primary molars in 80, 4-6-year-old children. The study population was randomly divided into case and control groups. In control group conventional pulpectomy was performed and in the case group working length was determined by …

OrthodonticsMolarElectronic apex locatorbusiness.industryResearchPulpectomy030206 dentistryRoot canal length:CIENCIAS MÉDICAS [UNESCO]Apex (geometry)Operative Dentistry and EndodonticsClinical study03 medical and health sciences0302 clinical medicineUNESCO::CIENCIAS MÉDICASMedicine030212 general & internal medicinebusinessGeneral DentistryConventional techniqueJournal of clinical and experimental dentistry
researchProduct

Three canals in the mesial root of mandibular first permanent molars: a clinical study

1989

Traditional teaching of the anatomy of root canals in different teeth can lead clinicians into the misguided belief that a predetermined number of root canals is always present in any given tooth. A new understanding of the root canal system has enabled the location of additional canals. Results of the clinical study of 760 first mandibular molars, showed that 20 (2.6 per cent) had three canals in the mesial root. Of these 20 teeth, 13 (65 per cent) had an intermediate canal which joined the mesiobuccal canal in the apical third. In six cases (30 per cent) it joined the mesiolingual canal in the same area. In only one case did the intermediate or third canal retain its individual nature and…

OrthodonticsMolarbusiness.industryRoot canalMandibleDentistryMandibleMesial rootMolarClinical studystomatognathic diseasesmedicine.anatomical_structurestomatognathic systemotorhinolaryngologic diseasesForamenmedicineHumanssense organsDental Pulp CavitybusinessGeneral DentistryInternational Endodontic Journal
researchProduct

Investigating activity of masticatory muscles in patients with hypermobile temporomandibular joints by using EMG

2014

Background: Temporomandibular joint hypermobility (TMJH) can manifest higher range of motions in mandible. The aim of this study was to investigate and compare the activity of masticatory muscle of TMJs in healthy individuals and patients with mild, moderate and severe TMJH. Material and Methods: In this clinical study, 69 patients (between the ages of 22 to 42) with manifestation of TMJH were included. The patients were divided into three groups based on their maximum mouth opening (MMO): (light) with MMO of 50-55 mm; (moderate) with MMO between 55 to 65 mm; and (severe) with MMO >65 mm. Also, 20 healthy people with profiled tomography in the last 6 months were invited as control group (he…

Orthodonticsbusiness.industryResearchMandibleOdontología:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludMasticatory forceClinical studyMouth openingstomatognathic systemHealthy individualsTemporomandibular joint hypermobilityUNESCO::CIENCIAS MÉDICASMedicineIn patientOral SurgerybusinessGeneral DentistryMasticatory muscle
researchProduct

Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study

2017

Schizophrenia is a chronic disease with a relatively high relapse rate. Different methods are introduced to improve compliance of the patients treated by psychiatrists; among them, a new and promising attitude is telepsychiatry. The 12-month clinical study of the compliance in paranoid schizophrenia was performed on the group of 199 patients. Every patient in the study was given a smartphone with the preinstalled original telemedicine platform (Telemedicine MoneoPlatform). The telemedicine system recorded every confirmation of the drug intake, and according to that, the compliance was counted as the percent of the doses of medication confirmed in relation to the planned ones. In the first m…

Paranoid schizophreniamedicine.medical_specialtyTelemedicinebusiness.industryTelepsychiatrytelepsychiatrymedicine.diseasecomplianceArticle030227 psychiatryClinical studyschizophrenia03 medical and health sciences0302 clinical medicineChronic diseaseTreatment complianceSchizophreniamental disordersPhysical therapyMedicineDrug intoxicationbusiness030217 neurology & neurosurgeryJournal of Technology in Behavioral Science
researchProduct